Pharmacologic effects and clinical evaluation of Tenapanor, a new drug for hyperphosphatemia
10.12092/j.issn.1009-2501.2023.12.014
- Author:
Wenping HOU
1
;
Wenping HOU
2
;
Lei XU
2
;
Changhai SU
2
Author Information
1. Graduate School of Baotou Medical College
2. Department of Pharmacy, Ordos Central Hospital
- Publication Type:Journal Article
- Keywords:
clinical evaluation;
ESRD;
hyperphosphatemia;
NHE3 inhibitor;
pharmacological effects;
Tenapanor
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(12):1429-1435
- CountryChina
- Language:Chinese
-
Abstract:
Tenapanor is a novel phosphorus-lowering drug, which mainly inhibits sodium/hydrogen exchange protein 3 (NHE3), and also reduces intestinal phosphorus absorption by down-regulating the expression of sodium phosphate co-transporter protein (NAPI). Tenapanor is mainly used for the treatment of hyperphosphatemia in patients with end-stage renal disease-hemodialysis (ESRD-HD). Diarrhea is the most common adverse reaction to this product. This article reviews Tenapanor by performing a literature search on its pharmacological effects, pharmacokinetic properties, clinical evaluation, safety, drug interactions and dosage.
